Genetic engineering involves the fusion of tumor-targeting or tumor-penetrating peptides with transmembrane proteins, including LAMP2B, PDGFR, PTGFRN, CD63, CD9, and CD81, on EVs and the expression of the fused protein in donor cells, which produce EVs with the functional peptides on the surface. This evidence concerns the gene CD9 and neoplasm.